Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Herceptin Adjuvant Breast Cancer Sales Slow In First Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

Genentech eyes additional opportunities for trastuzumab in adjuvant setting in node-positive, hormone receptor-positive breast cancer patients.

You may also be interested in...



Lucentis Wet AMD Growth May Cool In 2007, Genentech Says

Rapid uptake seen in 2006 is likely to level off this year as patients transition to lower dose frequency, according to the firm.

Herceptin Approved For Early-Stage Adjuvant Breast Cancer

The average cost per course of therapy in the adjuvant indication is significantly more than for metastatic cancer.

Genentech Plans Herceptin Early-Stage Breast Cancer Submission

Genentech is planning a supplemental BLA for Herceptin (trastuzumab) for adjuvant treatment of early stage breast cancer. Much-lauded Phase III data at American Society of Clinical Oncology meeting show significant reduction in disease recurrence and overall survival improvement of 49% at four years.

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel